Loading clinical trials...
Loading clinical trials...
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.
Conditions
Interventions
CSJ117
Placebo
Locations
113
United States
Novartis Investigative Site
Bakersfield, California, United States
Novartis Investigative Site
Huntington Beach, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Mission Viejo, California, United States
Start Date
September 9, 2020
Primary Completion Date
July 12, 2022
Completion Date
September 6, 2022
Last Updated
June 20, 2024
NCT07431021
NCT06003569
NCT02327897
NCT07486401
NCT07219173
NCT04706988
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions